Association between serum cholinesterase and the prevalence of atrial fibrillation in Chinese hypertensive population: a cross-sectional study.
Association
Atrial fibrillation
Fatty liver
Hypertension
Serum cholinesterase
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
08 Nov 2023
08 Nov 2023
Historique:
received:
04
05
2023
accepted:
25
10
2023
medline:
10
11
2023
pubmed:
9
11
2023
entrez:
8
11
2023
Statut:
epublish
Résumé
Atrial fibrillation (AF) is a very common arrhythmia with significant incidence rate and mortality. Several studies have shown a notable correlation between non-alcoholic fatty liver disease (NAFLD) and AF. It has been observed that serum cholinesterase (SChE) levels are elevated in individuals with fatty liver. However, the relationship between the SChE index and AF is still unclear. Therefore, the purpose of this study is to explore the association between the SChE index and the prevalence of AF in patients with hypertension. We collected cross-sectional data from January 2018 to April 2021 based on a retrospective study of cardiovascular disease. A total of 748 patients with hypertension were included, of whom 165 had AF. We used logistic regression models to test the relationship between SChE and the prevalence of AF in hypertensive patients. In hypertensive patients, the SChE index was significantly associated with AF (OR = 0.723, P < 0.001). After adjusting for potential confounding factors, this correlation was still significant (OR = 0.778, P < 0.001). The stability of the model was verified by adjusting the variable type of SChE. The data were further stratified according to whether the patient had fatty liver. In the stratified data, the correlation between SChE and atrial fibrillation was still significant (P < 0.05). Our study showed that SChE was significantly negatively correlated with the occurrence of AF in patients with hypertension. And this correlation was not affected by whether the patient had fatty liver.
Sections du résumé
BACKGROUND
BACKGROUND
Atrial fibrillation (AF) is a very common arrhythmia with significant incidence rate and mortality. Several studies have shown a notable correlation between non-alcoholic fatty liver disease (NAFLD) and AF. It has been observed that serum cholinesterase (SChE) levels are elevated in individuals with fatty liver. However, the relationship between the SChE index and AF is still unclear. Therefore, the purpose of this study is to explore the association between the SChE index and the prevalence of AF in patients with hypertension.
METHOD
METHODS
We collected cross-sectional data from January 2018 to April 2021 based on a retrospective study of cardiovascular disease. A total of 748 patients with hypertension were included, of whom 165 had AF. We used logistic regression models to test the relationship between SChE and the prevalence of AF in hypertensive patients.
RESULT
RESULTS
In hypertensive patients, the SChE index was significantly associated with AF (OR = 0.723, P < 0.001). After adjusting for potential confounding factors, this correlation was still significant (OR = 0.778, P < 0.001). The stability of the model was verified by adjusting the variable type of SChE. The data were further stratified according to whether the patient had fatty liver. In the stratified data, the correlation between SChE and atrial fibrillation was still significant (P < 0.05).
CONCLUSION
CONCLUSIONS
Our study showed that SChE was significantly negatively correlated with the occurrence of AF in patients with hypertension. And this correlation was not affected by whether the patient had fatty liver.
Identifiants
pubmed: 37941017
doi: 10.1186/s40001-023-01474-z
pii: 10.1186/s40001-023-01474-z
pmc: PMC10631021
doi:
Substances chimiques
Cholinesterases
EC 3.1.1.8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
500Subventions
Organisme : the Capital Health Development Scientific Research Special Project
ID : NO.2022-1-4153
Informations de copyright
© 2023. The Author(s).
Références
Stroke. 2017 Nov;48(11):3142-3144
pubmed: 28931618
Eur J Clin Pharmacol. 2008 Sep;64(9):895-900
pubmed: 18506436
Am J Cardiol. 2012 Jul 15;110(2):270-6
pubmed: 22503584
Cochrane Database Syst Rev. 2020 Oct 22;10:CD012569
pubmed: 33089502
Heart. 2019 Dec;105(24):1860-1867
pubmed: 31444267
Intern Med. 2019 Mar 15;58(6):809-812
pubmed: 30449782
Front Immunol. 2023 Jan 10;13:1098725
pubmed: 36703963
Ann Palliat Med. 2021 Nov;10(11):11714-11720
pubmed: 34872296
Vnitr Lek. 2021 Spring;67(E-2):4-8
pubmed: 34074098
Am J Clin Nutr. 2019 Aug 1;110(2):330-339
pubmed: 31161211
Scand J Clin Lab Invest. 2002;62(5):399-404
pubmed: 12387587
Circulation. 2020 Oct 13;142(15):e214-e233
pubmed: 32929996
Front Endocrinol (Lausanne). 2023 Jul 05;14:1160532
pubmed: 37476492
Int J Eat Disord. 2007 Dec;40(8):746-50
pubmed: 17610252
Arq Bras Endocrinol Metabol. 2013 Oct;57(7):533-7
pubmed: 24232818
Prog Cardiovasc Dis. 2022 Nov-Dec;75:4-11
pubmed: 36395880
Ann Hepatol. 2012 May-Jun;11(3):356-63
pubmed: 22481455
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Nat Rev Gastroenterol Hepatol. 2019 Sep;16(9):517-530
pubmed: 31278377
Clin Cardiol. 2018 Dec;41(12):1507-1512
pubmed: 30251368
Hepatology. 2004 Dec;40(6):1387-95
pubmed: 15565570
J Hypertens. 2020 May;38(5):839-844
pubmed: 31917714
JAMA. 2015 Jun 9;313(22):2263-73
pubmed: 26057287
Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38
pubmed: 34964875
J Cardiovasc Med (Hagerstown). 2014 May;15(5):377-83
pubmed: 24743688
Clin Res Hepatol Gastroenterol. 2017 Oct;41(5):525-532
pubmed: 28866089
Circ Res. 2017 Apr 28;120(9):1501-1517
pubmed: 28450367
Int J Cardiovasc Imaging. 2019 Jul;35(7):1277-1286
pubmed: 30923993
BMC Emerg Med. 2019 Sep 4;19(1):49
pubmed: 31484499
Europace. 2017 Jun 1;19(6):891-911
pubmed: 28881872
J Gastrointestin Liver Dis. 2019 Dec 09;28(4):483-493
pubmed: 31826063
Eur J Med Res. 2023 Sep 19;28(1):355
pubmed: 37726807
Liver Int. 2019 Apr;39(4):758-769
pubmed: 30657626
J Hepatol. 2022 Oct;77(4):931-938
pubmed: 35688226
Circulation. 2011 Apr 12;123(14):1501-8
pubmed: 21444879
Clin Chem. 2012 Jun;58(6):1055-8
pubmed: 22294734
Am J Hypertens. 2017 Aug 1;30(8):733-755
pubmed: 28338788
Biochimie. 2011 Mar;93(3):469-76
pubmed: 21094673
Eur Heart J. 2012 Sep;33(18):2282-9
pubmed: 22745355
Card Electrophysiol Clin. 2019 Dec;11(4):563-571
pubmed: 31706465
Cardiovasc Res. 2022 Jul 27;118(10):2281-2292
pubmed: 34358302
Clin Chim Acta. 2007 Mar;378(1-2):128-35
pubmed: 17182021
Biomed Res Int. 2017;2017:8153024
pubmed: 28785588
Mol Med. 2010 Jul-Aug;16(7-8):278-86
pubmed: 20464061
Int J Epidemiol. 2017 Feb 1;46(1):162-172
pubmed: 27143136
N Engl J Med. 2012 Jan 12;366(2):120-9
pubmed: 22236222
Circulation. 2014 Feb 25;129(8):837-47
pubmed: 24345399
Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):425-439
pubmed: 29713021
Curr Pharm Des. 2022;28(4):296-305
pubmed: 34766887
JAMA. 2018 Dec 18;320(23):2474-2475
pubmed: 30476962
BMC Public Health. 2020 Mar 30;20(1):420
pubmed: 32228532
Clin Lab. 2016;62(6):1093-9
pubmed: 27468571
Pharmacol Res. 2018 Feb;128:322-326
pubmed: 29055746
J Int Med Res. 2014 Apr;42(2):542-53
pubmed: 24595150